SCHEMBL6154958

SCHEMBL6154958

CSc1cc(N)ccc1C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
CYP3A4 P08684 2/20 0.41
ESR2 Q92731 1/20 0.41
PTPN1 P18031 1/20 0.41
THRB P10828 3/20 0.41
ALOX15 P16050 3/20 0.41
HSD17B10 Q99714 2/20 0.41
GFER P55789 2/20 0.41
YWHAG P61981 1/20 0.41
HTT P42858 1/20 0.40
TDP1 Q9NUW8 3/20 0.39
POLB P06746 2/20 0.39
PTGS2 P35354 2/20 0.38
SIRT1 Q96EB6 1/20 0.38
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16424167 0.85 KDM4E (0.55) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL19445594 0.85 KDM4E (0.45) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL4096751 0.79 KDM4E (0.50) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22246813 0.79 DGAT1 (0.55) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL4068010 0.79 CES2 (0.42) KDM4EMEN1KMT2AMAPTTDP1
SCHEMBL8621588 0.78 AR (0.45) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL15271227 0.76 LMNA (0.51) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL16424137 0.76 GAA (0.41) KDM4EMAPTALDH1A1GAACYP3A4
SCHEMBL2325301 0.75 KDM4E (0.47) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL1803658 0.74 MAPT (0.53) KDM4EMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 KDM4E 2017/4885MEN1 1993/4885KMT2A 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.